# Case Report: Intensity-modulated radiotherapy combined with immunotherapy for intramedullary spinal cord metastases of lung adenocarcinoma

## TL;DR

This case report describes a successful treatment of rare spinal cord metastases using a combination of radiotherapy and immunotherapy, resulting in improved quality of life for 10 months.

## Contribution

The novel contribution is the first reported use of IMRT combined with immunotherapy for intramedullary spinal cord metastases from lung cancer.

## Key findings

- The patient experienced a 10-month survival with a high quality of life after treatment.
- Combining IMRT and immunotherapy showed potential for managing rare spinal cord metastases.
- This case highlights the need for further research into treatment strategies for ISCMs.

## Abstract

Intramedullary spinal cord metastases (ISCMs) are rare in clinical practice and their presentation is usually an unfavorable sign with a median overall survival (mOS) of 3-4 months after diagnosis. Due to their rarity, heterogeneity and rapid progression, clinicians have few satisfactory guidelines or optimal management for ISCMs. Herein, we share a clinical experience of intensity-modulated radiotherapy (IMRT) combined with immunotherapy (IO) for ISCMs from lung adenocarcinoma (LUAD) that achieved a relatively high quality of life for 10 months, which has not been previously reported.